Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-1758 in participants with Alzheimer's disease
CTR20262643Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ABBV-1758 in Alzheimer's disease (AD), sponsored by AbbVie Inc.. Started Jul 2026; status: active.
02
Drugs
ABBV-1758
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20262643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262643.